ADTX
Aditxt Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
309,320
P/E Ratio
—
EPS
$-9230.64
Beta
1.17
52W High
$3164.00
52W Low
$0.53
50-Day MA
$3.71
200-Day MA
$412.64
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
0.35
PEG Ratio
—
About Aditxt Inc.
Aditxt Inc. is an innovative biotechnology company focused on advancing healthcare through its proprietary immune modulation and personalized medicine platform. The company is dedicated to enhancing immune system responses to combat chronic diseases and allergies, thereby improving patient outcomes. With a strong pipeline of therapeutic candidates backed by comprehensive research and strategic partnerships, Aditxt is strategically positioned to lead in the emerging field of immune-based therapies. By emphasizing scientific progress and patient-focused solutions, Aditxt aims to reshape the future of immunology and contribute significantly to the healthcare landscape.
Fundamentals
| Revenue (TTM) | 3,195 |
| Gross Profit (TTM) | 268 |
| EBITDA | $-19.30M |
| Operating Margin | -1098726.00% |
| Return on Equity | -699.00% |
| Return on Assets | -50.30% |
| Revenue/Share (TTM) | $0.09 |
| Book Value | $-151.87 |
| Price-to-Book | 0.07 |
| Price-to-Sales (TTM) | 96.81 |
| EV/Revenue | 66.42 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -86.60% |
| Shares Outstanding | 517,860 |
| Float | 824,840 |
| % Insiders | 2.16% |
| % Institutions | 0.81% |
Data last updated: 4/7/2026